openpr.com
Cure8 news brief
Why This Matters
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and market-size projections that reflect trends in diagnosis and treatment uptake.
Who Should Pay Attention
Adult patients with Crohn's disease, people on or considering biologic therapy, clinicians prescribing IBD treatments, and researchers or industry watchers tracking drug approvals and market trends.
Study Snapshot
Story typePress release
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This article is a market report summary (DelveInsight-based) about Crohn's disease covering epidemiology, market size and forecasts, recent regulatory approvals, and pipeline clinical results.
It lists recent FDA approvals of ustekinumab biosimilars (STEQEYMA, Imuldosa) and mentions clinical trial results for mirikizumab and guselkumab presented at UEG Week 2024. The report also summarizes market revenues, leading drugs (adalimumab), therapy class revenues, and companies involved in the Crohn's disease market.
The piece is a commercial market-analysis summary rather than original clinical research. It highlights approvals and Phase 3 trial readouts relevant to drug availability and future treatment options, and gives high-level epidemiology and market-size estimates. It does not provide patient-level clinical guidance or new clinical practice recommendations.
If you want details on any specific drug, trial, or regulatory approval mentioned here, look up the original DelveInsight report, the cited trial abstracts (UEG Week), or the FDA approval announcements for full source documents.
Keep In Mind
This is a market report / press summary aggregating regulatory approvals, company trial announcements, and sales/forecast estimates. It is not a clinical guideline or primary trial publication. For clinical decisions, consult original trial reports, regulatory documents, and your healthcare team.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
Indexed viaGoogle News
Source typePress release
PublishedFeb 6, 2025, 4:08 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Crohn's Disease Market Analysis 2034: Clinical Trials, EMA, - openPR.com
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...